Intensity-modulated radiation therapy for anal carcinoma;Radiothérapie conformationnelle avec modulation d'intensité des cancers de l'anus

Cancer/Radiotherapie

Volumn 15, Issue 6-7, 2011, Pages 549-554

  Peiffert, D ^a   Moreau Claeys, M V ^a   Tournier Rangeard, L ^a   Huger, S ^a   Marchesi, V ^a  

^a CENTRE ALEXIS VAUTRIN   (France)

Author keywords

Anal canal; IMRT; Radiotherapy; Squamous cell carcinoma

Indexed keywords

ANUS CARCINOMA; CANCER RADIOTHERAPY; DOSIMETRY; EVIDENCE BASED MEDICINE; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; CARCINOMA; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; MULTICENTER STUDIES AS TOPIC; ORGANS AT RISK; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES;

EID: 80053314261     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2011.07.240     Document Type: Short Survey

References (28)

1. Joly F., Degrendel A.C., Guizard A.V. Qualité de vie après radiothérapie pour un cancer localisé de la prostate. Cancer Radiother 2010, 14:519-525.
2. Martin E., Pointreau Y., Roche-Forestier S., Barillot I. Dose de tolérance à l'irradiation des tissus sains: intestin grêle. Cancer Radiother 2010, 14:350-353.
3. Tournier-Rangeard L., Mercier M., Peiffert D., Gérard J.P., Romestaing P., Lemanski C., et al. Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03). Radiother Oncol 2008, 87:391-397.
4. HAS. Haute Autorité de Santé. La radiothérapie conformationnelle avec modulation d'intensité. Saint-Denis: HAS; 2006.
5. Mahé MA. Investigateur coordonnateur. Évaluation médicoéconomique comparant la radiothérapie conformationnelle avec modulation d'intensité (RCMI) réalisée par tomothérapie hélicoïdale (Hi Art®) et arc thérapie dynamique (RapidArc®, VMAT®) dans les cancers pelviens avec irradiation ganglionnaire (prostate, col utérin, canal anal). 2011.
6. Nguyen B.T., Joon D.L., Khoo V., Quong G., Chao M., Wada M., et al. Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol 2008, 87:376-382.
7. Schwarz J.K., Siegel B.A., Dehdashti F., Myerson R.J., Fleshman J.W., Grigsby P.W. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 2008, 71:180-186.
8. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996, 348:1049-1054. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
9. Bartelink H., Roelofsen F., Eschwege F., Rougier P., Bosset J.F., Gonzalez D.G., et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997, 15:2040-2049.
10. Peiffert D., Giovannini M., Ducreux M., Michel P., Francois E., Lemanski C., et al. High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study. Ann Oncol 2001, 12:397-404.
11. Barillot I. Les cancers du col utérin: place de la radiothérapie avec modulation d'intensité. Cancer Radiother 2009, 13:507-510.
12. Drouet F., Lagrange J.L. Dose de tolérance à l'irradiation des tissus sains: la moelle osseuse. Cancer Radiother 2010, 14:392-404.
13. Myerson R.J., Garofalo M.C., El Naqa I., Abrams R.A., Apte A., Bosch W.R., et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009, 74:824-830.
14. Vordermark D., Schwab M., Ness-Dourdoumas R., Sailer M., Flentje M., Koelbl O. Association of anorectal dose-volume histograms and impaired fecal continence after 3D conformal radiotherapy for carcinoma of the prostate. Radiother Oncol 2003, 69:209-214.
15. Teguh D.N., Levendag P.C., Sewnaik A., Hakkesteegt M.M., Noever I., Voet P., et al. Results of fiberoptic endoscopic evaluation of swallowing vs. radiation dose in the swallowing muscles after radiotherapy of cancer in the oropharynx. Radiother Oncol 2008, 89:57-63.
16. Vordermark D. Potential and limitations of intensity-modulated radiotherapy in anal cancer. J Clin Oncol 2008, 26:688. [author reply-9.
17. Lin A., Ben-Josef E. Intensity-modulated radiation therapy for the treatment of anal cancer. Clin Colorectal Cancer 2007, 6:716-719.
18. Milano M.T., Jani A.B., Farrey K.J., Rash C., Heimann R., Chmura S.J. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005, 63:354-361.
19. Salama J.K., Mell L.K., Schomas D.A., Miller R.C., Devisetty K., Jani A.B., et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007, 25:4581-4586.
20. Chen Y.J., Liu A., Tsai P.T., Vora N.L., Pezner R.D., Schultheiss T.E., et al. Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol Phys 2005, 63:274-281.
21. Moreau-Claeys M.V., Peiffert D. Dose de tolérance à l'irradiation des tissus sains: le canal anal. Cancer Radiother 2010, 14:359-362.
22. Clivio A., Fogliata A., Franzetti-Pellanda A., Nicolini G., Vanetti E., Wyttenbach R., et al. Volumetric-modulated arc radiotherapy for carcinomas of the anal canal: a treatment planning comparison with fixed field IMRT. Radiother Oncol 2009, 92:118-124.
23. Joseph K.J., Syme A., Small C., Warkentin H., Quon H., Ghosh S., et al. A treatment planning study comparing helical tomotherapy with intensity-modulated radiotherapy for the treatment of anal cancer. Radiother Oncol 2010, 94:60-66.
24. Menkarios C., Azria D., Laliberte B., Moscardo C.L., Gourgou S., Lemanski C., et al. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol 2007, 2:41.
25. Kachnic L.A., Winter K.A., Myerson R.J., Goodyear M.D., Willins J., Esthappan J., et al. Two-year outcomes of RTOG 0529: a phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. J Clin Oncol 2011, 29:368. [ASCO Meeting Abstract].
26. Bazan J.G., Hara W., Hsu A., Kunz P.A., Ford J., Fisher G.A., et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011, 117:3342-3351.
27. Pepek J.M., Willett C.G., Wu Q.J., Yoo S., Clough R.W., Czito B.G. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys 2010, 78:1413-1419.
28. Wright J.L., Patil S.M., Temple L.K., Minsky B.D., Saltz L.B., Goodman K.A. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys 2010, 78:1064-1072.